Skip to main content
Skip to main menu Skip to spotlight region Skip to secondary region Skip to UGA region Skip to Tertiary region Skip to Quaternary region Skip to unit footer


Yan Daniel Zhao

University of Oklahoma Health Sciences Center at Tulsa

We present research on clinical trials with a sensitive subpopulation of patients, that is, a subgroup that is more likely to benefit from the treatment than the overall population. Given a sensitive subgroup defined by a prespecified classifier, for example, a clinical marker or pharmacogenomic marker, the trial’s outcome is declared positive if the treatment effect is established in the overall population or in the subgroup. We provide a summary of key considerations in clinical trials with a sensitive subgroup, including multiplicity and enrichment adjustments as well as optimality considerations in the analysis strategy. The methodology proposed in this article is illustrated using a neuroscience clinical trial and its operating characteristics are accessed via a simulation study. Key Words: Clinical trials; Enriched clinical trials; Sensitive population; Type I error rate control; Weighted power.

Support us

We appreciate your financial support. Your gift is important to us and helps support critical opportunities for students and faculty alike, including lectures, travel support, and any number of educational events that augment the classroom experience. Click here to learn more about giving.

Every dollar given has a direct impact upon our students and faculty.